3-hydroxy Darifenacin

• CAT Number: I020885
• CAS Number: 206048-82-0
• Molecular Formula: C28H30N2O3
• Molecular Weight: 442.56
• Purity: 95%
• Synonyms: 3-hydroxy Darifenacin, UK 148993
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-[(3S)-1-[2-(3-hydroxy-2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
• InChI: InChI=1S/C28H30N2O3/c29-27(32)28(21-7-3-1-4-8-21,22-9-5-2-6-10-22)23-14-16-30(18-23)15-13-20-11-12-26-24(17-20)25(31)19-33-26/h1-12,17,23,25,31H,13-16,18-19H2,(H2,29,32)/t23-,25?/m1/s1
• InChIKey: MQEQBFMESJKUBQ-XQZUBTRRSA-N
• SMILES: C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5O

3-Hydroxy Darifenacin（Cat No.:I020885）is a metabolite of Darifenacin, a selective muscarinic M3 receptor antagonist used to treat overactive bladder symptoms, such as urgency and incontinence. Darifenacin works by inhibiting acetylcholine binding to the M3 receptors in the bladder, reducing involuntary contractions. The 3-hydroxy form is produced during the metabolism of Darifenacin in the liver and is a major active metabolite. This metabolite retains some pharmacological activity and contributes to the drug’s overall therapeutic effects. 

Reference

1. Beaumont, K.C., Cussans, N.J., Nichols, D.J., et al. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 28(1), 63-75 (1998).
2. Kerbusch, T., Wählby, U., Milligan, P.A., et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. 56(6), 639-652 (2003).
3. Mansfield, K.J., Chandran, J.J., Vaux, K.J., et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J. Pharmacol. Exp. Ther. 328(3), 893-899 (2009).